Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease (2021)

First Author: Wellens J
Attributed to:  Phase 1 COVID-19 Immunity - National Core Study funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2021.10.13.21264916

Publication URI: http://dx.doi.org/10.1101/2021.10.13.21264916

Type: Preprint